All articles tagged with #zealand pharma
Originally Published 1 year ago — by Quartz
Zealand Pharma's stock rose 17% after announcing that its experimental weight loss drug petrelintide showed similar efficacy to Ozempic with fewer side effects in a phase 1 trial. Petrelintide, a long-acting amylin analog, could be an alternative for patients who can't tolerate GLP-1 treatments.
Originally Published 1 year ago — by CNBC
Zealand Pharma's shares surged 18% after positive early-stage trial results for its weight loss drug petrelintide, which showed an average body weight reduction of 8.6% compared to 1.7% with a placebo. The drug was deemed safe and well-tolerated, positioning it as a potential alternative to GLP-1 receptor agonist-based therapies like Novo Nordisk's Ozempic. The company plans to proceed with a phase 2 clinical trial.
Originally Published 1 year ago — by STAT
Boehringer Ingelheim and Zealand Pharma's drug, survodutide, has shown success in a Phase 2 study for the treatment of the liver condition MASH, with 83% of patients experiencing significant improvements compared to those who received a placebo. The study met its primary endpoint of improvements in MASH without the worsening of fibrosis, and secondary endpoints, including an improvement in fibrosis, were also achieved. This development comes amid increasing competition in the obesity medicine field.
Originally Published 1 year ago — by CNBC
Zealand Pharma's stock surged 32% after positive trial results for its weight-loss drug, survodutide, which also showed efficacy in treating liver inflammation caused by excess fat cells. The drug has received fast-track designation from the FDA and is undergoing five Phase-3 trials for people who are overweight or obese, positioning the company as a key player in the highly lucrative obesity therapeutics market alongside competitors like Novo Nordisk and Eli Lilly.